Please use this identifier to cite or link to this item:
Title: The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential
Authors: Fruchart, Jean-Charles
Santos, Raul D.
Aguilar-Salinas, Carlos
Aikawa, Masanori
Kodama, Tatsuhiko
Rasadi, Khalid Al
Amarenco, Pierre
Barter, Philip J.
Ceska, Richard
Corsini, Alberto
Després, Jean-Pierre
Duriez, Patrick
Eckel, Robert H.
Ezhov, Marat V.
Farnier, Michel
Ginsberg, Henry N.
Hermans, Michel P.
Ishibashi, Shun
Karpe, Fredrik
Koenig, Wolfgang
Krempf, Michel
Lim, Soo
Lorenzatti, Alberto J.
McPherson, Ruth
Nuñez-Cortes, Jesus Millan
Nordestgaard, Børge G.
Ogawa, Hisao
Packard, Chris J.
Plutzky, Jorge
Ponte-Negretti, Carlos I.
Pradhan, Aruna
Ray, Kausik K.
Reiner, Željko
Ridker, Paul M.
Ruscica, Massimiliano
Sadikot, Shaukat
Shimano, Hitoshi
Sritara, Piyamitr
Stock, Jane K.
Su, Ta-Chen
Susekov, Andrey V.
Tartar, André
Taskinen, Marja-Riitta
Tenenbaum, Alexander
Tokgözoğlu, Lale S.
Tomlinson, Brian
Tybjærg-Hansen, Anne
Valensi, Paul
Vrablík, Michal
Wahli, Walter
Watts, Gerald F.
Yamashita, Shizuya
Yokote, Koutaro
Zambon, Alberto
Libby, Peter
Keywords: Residual Cardiovascular Risk
Visceral Obesity
Issue Date: 2019
Source: Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Rasadi, K. A., Amarenco, P., . . . Libby, P. (2019). The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential. Cardiovascular Diabetology, 18(1), 71-. doi:10.1186/s12933-019-0864-7
Series/Report no.: Cardiovascular Diabetology
Abstract: In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.
DOI: 10.1186/s12933-019-0864-7
Rights: © 2019 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
The selective peroxisome.pdf1.88 MBAdobe PDFThumbnail

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.